Alternatives to Sirolimus If You Can't Fill Your Prescription

Sirolimus (brand name Rapamune) is an important immunosuppressant used to prevent kidney transplant rejection and treat a rare lung disease called LAM (lymphangioleiomyomatosis). For most patients, it's not something that can simply be stopped — the immune system's ability to reject a transplanted organ is always present, and consistent immunosuppression is essential.

That said, if you truly cannot find sirolimus and exhausted your options, there may be alternatives your transplant team can consider. This article is meant to inform — not to guide you toward making any changes on your own.

Never switch or stop your immunosuppressant without talking to your transplant doctor first.

Why Alternatives Require Careful Medical Oversight

Sirolimus works by inhibiting mTOR, a protein that controls immune cell growth. This mechanism is fundamentally different from drugs like tacrolimus and cyclosporine, which target calcineurin. These differences mean that switching isn't as simple as substituting one pill for another — it requires adjusting your entire immunosuppression strategy, usually monitored with blood levels.

Additionally, sirolimus is often prescribed specifically because a patient needs to avoid calcineurin inhibitors (e.g., due to kidney toxicity). In those cases, switching to tacrolimus isn't appropriate. Your transplant team will weigh all these factors.

Everolimus (Zortress): The Closest Alternative

Everolimus (brand name Zortress) is the alternative most similar to sirolimus. Like sirolimus, it's an mTOR inhibitor — in fact, it's a chemical derivative of sirolimus. It's FDA-approved for preventing rejection in kidney and liver transplant recipients.

Key similarities and differences:

• Same class, similar side effects: Both can cause mouth sores, elevated cholesterol, impaired wound healing, and low blood counts
• Shorter half-life: Everolimus has a shorter half-life than sirolimus, meaning blood levels can be adjusted more quickly
• Different dosing: Not directly interchangeable in mg-for-mg dosing; requires recalculation and blood level monitoring
• Often paired: Frequently combined with reduced-dose calcineurin inhibitors rather than used as a standalone replacement

Tacrolimus (Prograf): A Different Mechanism

Tacrolimus (brand name Prograf) is the most widely used immunosuppressant in transplant medicine. It works by inhibiting calcineurin — a completely different mechanism than sirolimus. Many transplant programs use tacrolimus as first-line therapy, with sirolimus reserved for patients who need to minimize calcineurin inhibitor exposure (e.g., to protect kidney function).

If you were switched to sirolimus specifically to protect your kidneys from tacrolimus toxicity, switching back isn't appropriate. But for patients on sirolimus for other reasons, tacrolimus may be an option your team considers.

Cyclosporine (Neoral, Gengraf): An Older Calcineurin Inhibitor

Cyclosporine is an older calcineurin inhibitor that preceded tacrolimus. It shares a mechanism with tacrolimus but has a different side effect and drug interaction profile. It has been used in transplant medicine for decades and is well-understood.

Like tacrolimus, cyclosporine would only be appropriate for patients where calcineurin inhibition is not contraindicated. It's generally considered less effective than tacrolimus for preventing rejection, but may be used in specific situations.

Mycophenolate Mofetil (CellCept): Often Used in Combination

Mycophenolate mofetil (MMF, brand name CellCept) is an antimetabolite that works by a different mechanism — it inhibits an enzyme needed for lymphocyte proliferation. It's most often used in combination regimens alongside a calcineurin inhibitor and a steroid.

MMF isn't typically used as a standalone replacement for sirolimus, but it may be part of an adjusted regimen if sirolimus is temporarily unavailable.

Belatacept (Nulojix): An IV-Administered Option

Belatacept (Nulojix) is a biologic immunosuppressant that works by blocking T-cell activation through a different pathway. It's given as a monthly IV infusion at an infusion center, rather than taken orally.

Belatacept carries a boxed warning for post-transplant lymphoproliferative disorder (PTLD) — particularly in patients who haven't had prior Epstein-Barr virus (EBV) exposure. It's approved for kidney transplant recipients and may be an option for select patients, particularly those who want to avoid calcineurin inhibitor toxicity and are EBV-positive.

For LAM Patients: No Direct Oral Alternative

Sirolimus was the first and only FDA-approved oral treatment for lymphangioleiomyomatosis (LAM) when it was approved in May 2015. While everolimus has been studied in LAM and shows activity, it's not FDA-approved for this indication as of 2026. If you have LAM and cannot find sirolimus, contact your pulmonologist urgently — they may be aware of everolimus alternatives or clinical trials.

What to Do First: Find Sirolimus Before Switching

Before considering a switch, exhaust your options for locating sirolimus. Use medfinder to quickly search pharmacies near you for availability. Contact your transplant coordinator, try specialty pharmacies, and ask about mail-order. Many patients who believe sirolimus is unavailable in their area find it within a few hours with the right search tools.

For a full step-by-step guide, see our article on

how to find sirolimus in stock near you

The Bottom Line

Alternatives to sirolimus exist — everolimus is the closest pharmacologically, while tacrolimus and cyclosporine offer different mechanisms. But every switch requires careful medical oversight and blood level monitoring. If you're having trouble finding sirolimus, your first call should be to your transplant coordinator, and your second should be to medfinder or a specialty pharmacy. Never modify your immunosuppression regimen on your own.